Global News

Icon releases Flex Advantage for patient randomization

Tuesday, January 19, 2016

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.

[Read More]

Digital Clinical Research is nearing a Tipping Point

Monday, January 18, 2016

The Pulse on Global Trials by Matthew Howes

Since I started writing this column two years ago, clinical research has seen modest improvements in failure rates of late stage trials, but for the most part drug development remains unnecessarily expensive and inefficient. 

[Read More]

Eagle, AMRI partner on parenteral drug products

Friday, January 15, 2016

Eagle Pharmaceuticals and Albany Molecular Research (AMRI), a global CMO, have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the U.S., which will significantly expand Eagle’s portfolio of existing products and product candidates targeting therapeutic areas including oncology, critical care and orphan diseases.

[Read More]

Boehringer Ingelheim, Arena collaborate on schizophrenia research

Wednesday, January 13, 2016

Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors. An “orphan receptor” is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified.

[Read More]

Halloran Consulting Group adds CMO Mark Weinberg

Tuesday, January 12, 2016

Halloran Consulting Group has expanded its strategic capabilities with the addition of Mark Weinberg, M.D., MBA, who will serve as chief medical officer (CMO) and managing director. The addition of Weinberg to Halloran’s advisory services creates a unique offering to life sciences companies seeking CMO expertise as a key part of an on-demand, integrated development team.

[Read More]